SELLAS reports 41% death‑risk reduction and median overall survival gain in Phase 3 AML vaccine trial

SELLAS Life Sciences announced that its galinpepimut‑S (GPS) vaccine met the primary overall‑survival endpoint in the Phase 3 REGAL trial for acute myeloid leukemia. The vaccine cut the risk of death by 41% (hazard ratio 0.59) and extended median overall survival to 24.0 months versus 14.7 months with best‑available treatment. The company will meet the FDA to discuss an accelerated filing and plans a Biologics License Application in the first half of 2027.

The company said the results will be presented to the FDA to pursue an accelerated approval pathway, which could bring a new therapy to a high‑need AML population and drive further upside for shareholders.

  • 1The REGAL trial showed a 41% reduction in risk of death (hazard ratio 0.59).
  • 2Median overall survival was 24.0 months for GPS‑treated patients versus 14.7 months for the control arm.
  • 3The primary endpoint was met with a two‑sided p‑value of 0.035.
  • 4SELLAS plans to discuss an accelerated FDA filing and submit a Biologics License Application in the first half of 2027.
  • 5Shares surged more than 220% in pre‑market trading after the announcement.
  • 6The stock traded at $20.20, up 170.42%, on volume of over 72 million shares.

Sources